The need-to-know this morning
- Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on results of a Phase 1/2 trial.
- Johnson & Johnson said it will acquire Proteologix, a privately-held biotech focused on immune-mediated diseases, for $850 million with potential for additional milestone payments.
- Novartis said it’s met all tender offer conditions to acquire German biotech Morphosys.
Roche shares up on early obesity results
The Swiss pharma company reported this morning that its recently acquired obesity drug led to a placebo-adjusted weight loss of 18.8% in a 24-week Phase 1 trial.
(For context, in Phase 3 trials lasting over a year, the difference in weight loss between Wegovy and placebo was 12.4 percentage points, and in the Zepbound trial, it was 17.8 percentage points. It’s difficult to compare across trials, though, especially across different development stages.)
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.